Sherine Maher Rizk

Sherine Maher Rizk

Auto-generated profile, based on publicly available information

Sherine Maher Rizk

Biochemistry Department, Faculty of Pharmacy Cairo University Cairo Egypt

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
NANourhan M. Abdelmaksoud
Nourhan M. Abdelmaksoud
AAAhmed Ibrahim Abulsoud
Ahmed Ibrahim Abulsoud
TATamer M. Abdelghany
Tamer M. Abdelghany
SEShereen Saeid Elshaer
Shereen Saeid Elshaer
SRSherine Maher Rizk
Sherine Maher Rizk
MSMahmoud A. Senousy
Mahmoud A. Senousy

3 July 2013 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
PDF file
TMTarek K Motawi
Tarek K Motawi
SRSherine Maher Rizk
Sherine Maher Rizk
IIIhab Abdel‐Rahman Ibrahim
Ihab Abdel‐Rahman Ibrahim
YEYasmin Farid El‐Emady
Yasmin Farid El‐Emady

1 November 2021 in Life Sciences
Verified
Journal Article
Closed access
DFDoaa Fathi
Doaa Fathi
AAAhmed I. Abulsoud
Ahmed I. Abulsoud
MSMuhammed A. Saad
Muhammed A. Saad
NNNoha N. Nassar
Noha N. Nassar
MMMina M. Maksimos
Mina M. Maksimos
MSMahmoud A. Senousy
Mahmoud A. Senousy

4 July 2024 in Experimental Cell Research
Verified
Journal Article
Closed access
NANourhan M. Abdelmaksoud
Nourhan M. Abdelmaksoud
AAAhmed Ibrahim Abulsoud
Ahmed Ibrahim Abulsoud
TATamer M. Abdelghany
Tamer M. Abdelghany
SEShereen Saeid Elshaer
Shereen Saeid Elshaer
SRSherine Maher Rizk
Sherine Maher Rizk
NMNadine W. Maurice
Nadine W. Maurice

18 December 2024 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
NANourhan M. Abdelmaksoud
Nourhan M. Abdelmaksoud
AAAhmed I. Abulsoud
Ahmed I. Abulsoud
TATamer M. Abdelghany
Tamer M. Abdelghany
SEShereen Saeid Elshaer
Shereen Saeid Elshaer
ASAhmed Samaha
Ahmed Samaha
MSMahmoud A. Senousy
Mahmoud A. Senousy

1 November 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NSNagwa Shehata
Nagwa Shehata
DEDina Mohamed Abd El-Salam
Dina Mohamed Abd El-Salam
RHRoqaya Mahmoud Hussein
Roqaya Mahmoud Hussein
SRSherine Maher Rizk
Sherine Maher Rizk
3-nitropropionic acid (3-NP) is a potent mitochondrial inhibitor mycotoxin. Systemic administration of 3-NP can induce Huntington’s disease (HD)-like symptoms in experimental animals. Safranal (Safr) that is found in saffron essential oil has antioxidant, anti-inflammatory and anti-apoptotic actions. Candesartan (Cands) is an angiotensin receptor blocker that has the potential to prevent cognitive deficits. The present study aims to investigate the potential neuroprotective efficacy of Safr or Cands in 3-NP-induced rat model of HD. The experiments continued for nine consecutive days. Rats were randomly assigned into seven groups. The first group (Safr-control) was daily intraperitoneally injected with paraffin oil. The second group (Cands- and 3-NP-control) daily received an oral dose of 0.5% carboxymethylcellulose followed by an intraperitoneal injection of 0.9% saline. The third and fourth groups received a single daily dose of 50 mg/kg Safr (intraperitoneal) and 1 mg/kg Cands (oral), respectively. The sixth group was daily treated with 50 mg Safr kg/day (intraperitoneal) and was intraperitoneally injected with 20 mg 3-NP/ kg, from the 3rd till the 9th day. The seventh group was daily treated with 1 mg Cands /kg/day (oral) and was intraperitoneally injected with 20 mg 3-NP/ kg, from the 3rd till the 9th day. The present results revealed that 3-NP injection induced a considerable body weight loss, impaired memory and locomotor activity, reduced striatal monoamine levels. Furthermore, 3-NP administration remarkably increased striatal malondialdehyde and nitric oxide levels, whereas markedly decreased the total antioxidant capacity. Moreover, 3-NP significantly upregulated the activities of inducible nitric oxide synthase and caspase-3 as well as the Fas ligand, in striatum. On the contrary, Safr and Cands remarkably alleviated the above-mentioned 3-NP-induced alterations. In conclusion, Safr and Cands may prevent or delay the progression of HD and its associated impairments through their antioxidant, anti-inflammatory, anti-apoptotic and neuromodulator effects.